Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many income investors, questions about the sustainability of the dividend persist.

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with ...

The UK’s voluntary scheme for branded medicines pricing, access and growth (known as VPAG) makes sure that the NHS does not ...

Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored ...

Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...

Tánaiste Simon Harris has said the introduction of the new US tariff on EU goods provides "some degree of certainty" to businesses.

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

Pfizer CEO Albert Bourla said his company is in “very active discussions” over Trump’s request concerning most-favoured-nation pricing, according to news website FiercePharma. Bourla said he had ...

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.